Drug application
LEVOXYL (LEVOTHYROXINE SODIUM)
Drugs@FDA NDA 021301 · KING PHARMS
Key facts
| Drug name | LEVOXYL |
|---|---|
| Active ingredients | LEVOTHYROXINE SODIUM |
| Application type | NDA |
| Application number | 021301 |
| Company | KING PHARMS |
| Dosage forms | TABLET, ORAL |
| Strength | 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium |
| Marketing status | Prescription |
| TE codes | AB1, AB3 |
| Reference listed drug | Yes |
| Latest submission class | Type 5 - New Formulation or New Manufacturer |
| Latest submission status date | May 25, 2001 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 10–99 Products
- 10–99 Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: